Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

The authors describe the drug–drug interaction profile of the he patitis C direct‐acting antiviral agents ABT‐450, ombitasvir, and dasabuvir with cyclosporine A and tacrolimus, and use pha rmacokinetic simulations to develop recommendations for reduced doses of cyclosporine A and tacrolimus in postt...

Descripción completa

Detalles Bibliográficos
Autores principales: Badri, P., Dutta, S., Coakley, E., Cohen, D., Ding, B., Podsadecki, T., Bernstein, B., Awni, W., Menon, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024008/
https://www.ncbi.nlm.nih.gov/pubmed/25708713
http://dx.doi.org/10.1111/ajt.13111
_version_ 1782453725572366336
author Badri, P.
Dutta, S.
Coakley, E.
Cohen, D.
Ding, B.
Podsadecki, T.
Bernstein, B.
Awni, W.
Menon, R.
author_facet Badri, P.
Dutta, S.
Coakley, E.
Cohen, D.
Ding, B.
Podsadecki, T.
Bernstein, B.
Awni, W.
Menon, R.
author_sort Badri, P.
collection PubMed
description The authors describe the drug–drug interaction profile of the he patitis C direct‐acting antiviral agents ABT‐450, ombitasvir, and dasabuvir with cyclosporine A and tacrolimus, and use pha rmacokinetic simulations to develop recommendations for reduced doses of cyclosporine A and tacrolimus in posttransplant patients with recurrent hepatitis C infection.
format Online
Article
Text
id pubmed-5024008
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50240082016-09-23 Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir Badri, P. Dutta, S. Coakley, E. Cohen, D. Ding, B. Podsadecki, T. Bernstein, B. Awni, W. Menon, R. Am J Transplant Original Articles The authors describe the drug–drug interaction profile of the he patitis C direct‐acting antiviral agents ABT‐450, ombitasvir, and dasabuvir with cyclosporine A and tacrolimus, and use pha rmacokinetic simulations to develop recommendations for reduced doses of cyclosporine A and tacrolimus in posttransplant patients with recurrent hepatitis C infection. John Wiley and Sons Inc. 2015-05 2015-02-23 /pmc/articles/PMC5024008/ /pubmed/25708713 http://dx.doi.org/10.1111/ajt.13111 Text en © 2015 The Authors. American Journal of Transplantation Published by The American Society of Transplantation and the American Society of Transplant Surgeons This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Badri, P.
Dutta, S.
Coakley, E.
Cohen, D.
Ding, B.
Podsadecki, T.
Bernstein, B.
Awni, W.
Menon, R.
Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title_full Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title_fullStr Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title_full_unstemmed Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title_short Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir
title_sort pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with abt‐450, ombitasvir, and dasabuvir
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024008/
https://www.ncbi.nlm.nih.gov/pubmed/25708713
http://dx.doi.org/10.1111/ajt.13111
work_keys_str_mv AT badrip pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT duttas pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT coakleye pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT cohend pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT dingb pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT podsadeckit pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT bernsteinb pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT awniw pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir
AT menonr pharmacokineticsanddoserecommendationsforcyclosporineandtacrolimuswhencoadministeredwithabt450ombitasviranddasabuvir

Ejemplares similares